Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Global Blood Therapeutics Inc (GBT) USD0.001

Sell:$46.52 Buy:$46.53 Change: $0.56 (1.22%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
Sell:$46.52
Buy:$46.53
Change: $0.56 (1.22%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
Sell:$46.52
Buy:$46.53
Change: $0.56 (1.22%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Contact details

Address:
171 Oyster Point Blvd Ste 300
SOUTH SAN FRANCISCO
94080-1910
United States
Telephone:
+1 (650) 7417700
Website:
www.globalbloodtx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GBT
ISIN:
US37890U1088
Market cap:
$2.83 billion
Shares in issue:
60.02 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ted Love
    President, Chief Executive Officer, Director
  • Jeffrey Farrow
    Chief Financial Officer
  • Peter Radovich
    Senior Vice President, Operations
  • Jung Choi
    Chief Business and Strategy Officer
  • David Johnson
    Chief Commercial Officer
  • Tricia Suvari
    Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.